Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Nicolas Girard et al.|New England Journal of Medicine|2024Cited by 369
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81